Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
24/06/2026 20:00
BRIEF-Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia June 24 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
TRYNGOLZA® (OLEZARSEN) APPROVED BY THE FDA AS THE FIRST AND ONLY TREATMENT TO REDUCE TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
IONIS PHARMACEUTICALS - TRYNGOLZA AVAILABLE IN 50 MG OR 80 MG DOSE, SELF-ADMINISTERED MONTHLY
IONIS PHARMACEUTICALS - TRYNGOLZA TO BE AVAILABLE IN U.S. FOR SHTG IN JULY
Source text: ID:nBw9X7BDLa
Further company coverage: IONS.O
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors